DOCSLIB.ORG

Appendix 6 – Characteristics and Safety Data from the Included Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix 6 – Characteristics and Safety Data from the Included Studies BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Appendix 6 – Characteristics and safety data from the included studies How safe are topical corticosteroids compared to emollient or vehicle? Study ID Study design and Intervention and Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events (Systematic study duration comparator review*) (Quality assessment) Very potent topical corticosteroids Breneman 2003 RCT Intervention: Clobetasol Severity: moderate Local application site skin Unspecified adverse events (1) propionate 0.05% lotion (twice a to severe reactions Incidence comparable between 2 weeks treatment, then day) (n=96) No clinically significant groups. (unpublished) followed up for Age: ≥ 12 years telangiectasia or skin thinning additional 2 weeks Intervention: Clobetasol Treatment-related adverse (Feldman 2005 Sample size: 229 propionate 0.05% emollient events (2) Nankervis (3)) Cochrane risk of bias tool: participants cream (twice a day) (n=100) Clobetasol lotion = 4/96 patients randomisation described, (4.2%); Clobetasol cream = 1/100 allocation concealment Comparator: Vehicle (n=33) patients (1%) unclear, intention-to- Vehicle = 6/33 patients (18.2%) treat unclear. (Difference between groups: p= 0.0006a) Kimball 2008 (4) RCT Intervention: Clobetasol Severity: not Incidence of adverse events or (trial a) propionate emulsion specified in the treatment related adverse Duration not specified in formulation foam 0.05% review events (Frangos 2008 review Clobetasol foam = 8% (5)) Comparator: Vehicle Age: not specified in Risk of bias not assessed Vehicle foam = 10% the review in any of the included (no significant differences systematic reviews. Sample size: not between groups) specified in the review Rosso 2009 (6) RCT Intervention: Fluocinonide 0.1% Severity: not Skin thinning cream (n=109) specified in the Fluocinonide: 6/109 participants (Barnes 2009 (7)) 2 weeks treatment review (5.6%) Comparator: Vehicle (n=50) Risk of bias not assessed Vehicle: 2/50 participants (4.3%) Age: not specified in in any of the included (Difference between groups: the review systematic reviews. p=0.69a) Sample size: 159 participants www.olux- Single arm study Intervention: Clobetasol Severity: ≥30% BSA HPA axis suppression e.com (online (observational) propionate emollient foam 6/37 patients (16%) Age: data) (8) (twice daily) (n=37) ≥12 years old (not specified in the review how 2 weeks treatment Sample size: 37 it was measured) (Frangos 2008 Comparator: No comparator participants (5)) Axon E, et al. BMJ Open 2021; 11:e046476. doi: 10.1136/bmjopen-2020-046476 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Risk of bias not assessed in any of the included systematic reviews. Kimball 2008 (4) Open label Phase II safety Intervention: Clobetasol Severity: mild to HPA axis suppression (trial b) study propionate emollient foam severe 7/30 (23.3%) had adrenal 0.05% (twice daily) (n=52) insufficiency (ACTH stimulation (Frangos 2008 2 weeks treatment Age: children (from testing, measuring serum cortisol (5); Wood Comparator: No comparator 6 years old) and Risk of bias not assessed levels). Heickman 2018 adults in any of the included 47% of children (aged 6-11) (9)) systematic reviews. Sample size: 52 0% of adolescents (aged 12- participants 17) 27% of adults ( ≥18 years) Was reported as transient and reversible. After TCS discontinuation, children with biochemical adrenal insufficiency had complete resolution at retesting. Herz 1991 (10) Single arm study Intervention: Clobetasol Severity: not Skin thinning 1 case of skin (observational) propionate (n=59) specified in the thinning reported (not clear if in a (Barnes 2015 (7)) review psoriasis or eczema patient – but (2 weeks treatment) Comparator: No comparator assume its eczema as this is the Age: not specified in Risk of bias not assessed topic of the systematic review). the review in any of the included systematic reviews. Sample size: 59 participants Potent topical corticosteroids Sugarman 2009 RCT Intervention: Fluticasone 0.05% Severity: moderate Serious adverse events (11) cream twice daily to severe The participants did not report (4 weeks treatment) (hydrocortisone 2.5% for the any in either group. (Van Zuuren Age: children 6 (Cochrane risk of bias face and body folds) (n=62) 2017 (12)) months to 18 years No further details regarding tool: low risk of selection, Comparator: Ceramide- (mean age 7.1 years) other possible treatment related attrition and other dominant barrier repair adverse events were reported. biases. Unclear risk of Sample size: 121 formulation (EpiCeram) twice reporting and participants daily (emollient) (n=59) performance bias, High risk of detection bias. (12)) (Cochrane risk of bias tool: unclear risk of selection bias, high risk from no blinding. (3)) Axon E, et al. BMJ Open 2021; 11:e046476. doi: 10.1136/bmjopen-2020-046476 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Griffiths 2002 (13) RCT Intervention: Hydrocortisone Severity: not No difference in cutaneous Unspecified adverse events 17-butyrate cream (0.1%) specified adverse events which were Hydrocortisone group: 20/49 (Nankervis 2017 (up to 14 days treatment) maximum application of 2g (four possibly or probably related to (40.8%) participants reported 41 (3)) Age: adults ≥18 (Cochrane risk of bias fingertip units) per day (n=49) treatment in either group (p = adverse events in total. years old tool: low risk of selection 0.13) Emollient: 29/52 (55.8%) Comparator: Cipamfylline cream bias from sequence Sample size: 103 participants reported 63 adverse (1.5 mg of cipamfylline per gram The adverse events were mostly generation, unclear risk participants events in total. of cream) used up to a application site reactions, of selection bias from (Difference between groups: p= maximum of 2 g (four fingertip including itching, stinging or allocation concealment, 0.14 a) units) of cream per day burning, and drug reactions. low risk from blinding. (3)) (emollient) (n=54) Eichenfield 2006 RCT Intervention: Fluticasone Severity: moderate Withdrawal due to adverse (14) propionate four times daily to severe events (4 weeks treatment) (n=221) Topical corticosteroids: 4 (Nankervis 2017 Age: children from 3 Risk of bias not assessed participants in total from this (3)) Comparator: Vehicle four times months old to 16 study and from Hebert 2007 daily (n=217) years old The number of participants Sample size: 438 reporting at least 1 adverse children event Fluticasone: 77/221 (34.8%) participants Vehicle: 82/217 (37.8%) participants (Difference between groups: p=0.52a) Wu 2013 (15) RCT Intervention: Mometasone Severity: all None of the safety tests (e.g. full No clinical adverse events were furoate 0.1% cream, twice a day severities blood count, kidney and liver reported. (Nankervis 2017 (10 days treatment) (n=20) function test, and (3), Fishbein Age: children from 1 (Cochrane risk of bias electrocardiogram) showed any 2019 (16)) Comparator: placebo of distilled month to 1 year old tool: low risk of selection significant differences compared water in 1% dimethyl sulfoxide bias from sequence Sample size: 60 with baseline for all three mixed with the identical cream generation. Unclear risk participants treatment groups. base as used for the 15(R/S)- of selection bias from methyl-lipoxin A4 (n=20) allocation concealment, unclear risk from blinding Comparator: 15(R/S)-methyl- and other biases: Two lipoxin A4 0.1% cream (n=20) out of 60 participants were excluded from the analyses as they used concomitant medication (3)) Axon E, et al. BMJ Open 2021; 11:e046476. doi: 10.1136/bmjopen-2020-046476 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Pellanda 2005 RCT Intervention: Triamcinolone Severity: mild to Skin changes (17) acetonide moderate One report by a participant using (Duration not specified in placebo (no further details) (Nankervis 2017 the review) Comparator: Vehicle Age: not specified in (3)) the review Risk of bias not assessed Sample size: not specified in the review Lebwohl 1996 RCT Intervention: Fluticasone Severity: not The review authors only reported (18) propionate ointment 0.005% specified in the that “Drug related adverse (29 days treatment) review effects were rare” (Hoare 2000 (19)) Comparator: Vehicle (Moher 1995 quality Age: not specified in checklist: method and the review concealment of randomisation unclear, Sample size: 203 double blinded, large participants number of withdrawals and dropouts, no ITT analysis (19)) Lebwohl 1999 RCT Intervention: Fluticasone Severity: not The review authors only reported (20) propionate ointment 0.005% specified in the that “Drug related adverse (29 days treatment) review effects were rare” (Hoare 2000 (19)) Comparator: Vehicle (Moher 1995 quality Age: not specified in checklist: method and the review concealment of randomisation unclear, Sample size: 169 double blinded, large participants
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • 1532 Corticosteroids
    1532 Corticosteroids olone; Ultraderm; Malaysia: Synalar†; Mex.: Cortifung-S; Cortilona; Gr.: Lidex; Ital.: Flu-21†; Topsyn; Mex.: Topsyn; Norw.: Metosyn; Pharmacopoeias. In Br. Cremisona; Farmacorti; Flumicin; Fluomex; Fusalar; Lonason; Synalar; Philipp.: Lidemol; Lidex; Singapore: Lidex†; Spain: Klariderm†; Novoter; BP 2008 (Fluocortolone Hexanoate). A white or creamy-white, Norw.: Synalar; NZ: Synalar; Philipp.: Aplosyn; Cynozet; Synalar; Syntop- Switz.: To p s y m ; To p s y m i n ; UK: Metosyn; USA: Lidex; Vanos. ic; Pol.: Flucinar; Port.: Oto-Synalar N; Synalar; Rus.: Flucinar (Флуцинар); odourless or almost odourless, crystalline powder. It exhibits pol- Multi-ingredient: Austria: Topsym polyvalent; Ger.: Jelliproct; Topsym ymorphism. Practically insoluble in water and in ether; very Sinaflan (Синафлан); S.Afr.: Cortoderm; Fluoderm; Synalar; Singapore: polyvalent; Hung.: Vipsogal†; Israel: Comagis; Mex.: Topsyn-Y; Philipp.: Flunolone-V; Spain: Co Fluocin Fuerte; Cortiespec; Fluocid Forte; Fluoder- Lidex NGN; Spain: Novoter Gentamicina; Switz.: Mycolog N; Topsym slightly soluble in alcohol and in methyl alcohol; slightly soluble mo Fuerte; Flusolgen; Gelidina; Intradermo Corticosteroi†; Synalar; Synalar polyvalent; UK: Vipsogal. in acetone and in dioxan; sparingly soluble in chloroform. Pro- Rectal Simple; Swed.: Synalar; Switz.: Synalar; Thai.: Cervicum; Flu- ciderm†; Flunolone-V; Fulone; Supralan; Synalar; UK: Synalar; USA: Capex; tect from light. Derma-Smoothe/FS; DermOtic; Fluonid; Flurosyn†; Retisert; Synalar; Syn- emol; Venez.: Bratofil; Fluquinol Simple†; Neo-Synalar; Neoflu†. Fluocortin Butyl (BAN, USAN, rINNM) ⊗ Fluocortolone Pivalate (BANM, rINNM) ⊗ Multi-ingredient: Arg.: Adop-Tar†; Tri-Luma; Austria: Myco-Synalar; Procto-Synalar; Synalar N; Belg.: Procto-Synalar; Synalar Bi-Otic; Braz.: Butil éster de la fluocortina; Butylis Fluocortinas; Fluocortine Fluocortolone, pivalate de; Fluocortolone Trimethylacetate; Dermobel†; Dermoxin; Elotin; Fluo-Vaso; Neocinolon; Otauril†; Otocort†; Butyle; SH-K-203.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Clobetasone Butyrate, a New Topical Corticosteroid: Clinical Activity and Effects on Pituitary-Adrenal Axis Function and Model of Epidermal Atrophy
    626 BRITISH MEDICAL JOURNAL 13 SEPTEMBER 1975 17 Anderson, J. R., Goudie, R. B., and Gray, K. G., British J7ournal of 21 Temple, R., et al., Mayo Clinic Proceedings, 1972, 47, 872. Experimental Pathology, 1960, 41, 364. 22 Carlson, H. E., Temple, R., and Robbins, J., Journal of Clinical Endo- Br Med J: first published as 10.1136/bmj.3.5984.626 on 13 September 1975. Downloaded from 18 Fulthorpe, A. J., et al., Journal of Clinical Pathology, 1961, 14 654. crinology and Metabolism, 1973, 36, 1251. 19 Holborow, E. J., et al., British J7ournal of Experimental Pathology, 1959, '3 Cotton, G.. E., Gorman, C. A., and Mayberry, W. E., New England 40, 583. Journal of Medicine, 1971, 285, 529. 20 Evered, D. C., et al., British Medical.Journal, 1973, 1, 657. 24 Utiger, R. D., Journal of Clinical Investigation, 1965, 44, 1277. Clobetasone Butyrate, A New Topical Corticosteroid: Clinical Activity and Effects on Pituitary-Adrenal Axis Function and Model of Epidermal Atrophy D. D. MUNRO, LYN WILSON British Medical Journal, 1975, 3, 626-628 Studies THE DRUG Summary ClobetasQne butyrate is 21-chloro-11 dehydro betamethasone 17- butyrate. It was selected for study because screening tests indicated a Clobetasone butyrate is a new corticosteroid, selected separation of topical from systemic activity. The comparative values for study because of its combitation of good activity in for topical and systemic activityl of clobetasone butyrate and five the vasoconstriction test and low systemic activity in other steroids are given in the table (in arbitrary units). animals. Formulated as an 005o% ointment and cream (MolivateN it was clinically effective in patients with Comparative Topical (Vasoconstriction) and Systemic (Thymus Involution) eczema, its activity being significantly greater than that Activities of Six Corticosteroids of hydrocortisone 1% or fluocortolone 020°, (Ultradil).
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Cell Culture Spinner Flasks
    Europäisches Patentamt & (19) European Patent Office Office européen des brevets (11) EP 1 736 536 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.12.2006 Bulletin 2006/52 C12M 3/04 (2006.01) (21) Application number: 06117829.9 (22) Date of filing: 22.09.2000 (84) Designated Contracting States: • Flickinger, John AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Beverly MC NL PT SE MA 01915 (US) (30) Priority: 24.09.1999 US 405477 (74) Representative: Gill, Siân Victoria et al Venner Shipley LLP (62) Document number(s) of the earlier application(s) in 20 Little Britain accordance with Art. 76 EPC: London EC1A 7DH (GB) 00963738.0 / 1 222 248 Remarks: (71) Applicant: Cytomatrix, LLC This application was filed on 25-07-2006 as a Woburn, MA 01801 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Upton, Todd Chestnut Hill MA 02467 (US) (54) Cell culture spinner flasks (57) The present invention relates to culturing devic- es that are compact, utilize small amounts of cell culture media to establish and maintain cell cultures, and pro- duce a large number of cells in a short period of time when compared to other cell culturing devices and tech- niques. Such devices are useful in the culture of all cell types, but are particularly useful in the culture of cells that are known in the art to be difficult to culture, including cells that lose one or more of their particular attributes/ characteristics (e.g., pluripotentiality), or cells that are difficult to establish cultures of (e.g.
    [Show full text]
  • Pharmacokinetics of Ophthalmic Corticosteroids
    British Journal ofOphthalmology 1992; 76: 681-684 681 MINI REVIEW Br J Ophthalmol: first published as 10.1136/bjo.76.11.681 on 1 November 1992. Downloaded from Pharmacokinetics of ophthalmic corticosteroids Corticosteroids have been used by ophthalmologists with an identical vehicle, the aqueous humour concentrations of increasing frequency over the past 30 years, with the these steroids are almost identical.'9 None the less it is concomitant development of a diverse range of drop, essential when considering such empirical data, to recall that ointment, subconjunctival, and oral preparations. Though the systemic anti-inflammatory effect of both betamethasone the clinical benefits and side effects of such corticosteroid and dexamethasone is five to seven times that of predniso- preparations have been well documented, their basic lone.39"' The local anti-inflammatory potency of ocular pharmacokinetics in the human eye have yet to be fully steroids has yet to be fully investigated and whilst early work established. Indeed most of our pharmacokinetic knowledge suggested that prednisolone acetate 1% had the greatest anti- of these drugs has been elucidated by extrapolation of data inflammatory effect in experimental keratitis,'7 later studies obtained from rabbit experiments.1-26 These results can be demonstrated that fluorometholone acetate in a 1% formu- significantly disparate from human data because of the lation was equally efficacious in the same model.26 However, thinner rabbit cornea, lower rabbit blink rate, effect of prednisolone
    [Show full text]
  • Pre - PA Allowance Age 18 Years of Age Or Older Quantity 60 Grams Every 90 Days ______
    DOXEPIN CREAM 5% (Prudoxin, Zonalon) Pre - PA Allowance Age 18 years of age or older Quantity 60 grams every 90 days _______________________________________________________________ Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: Moderate pruritus, due to atopic dermatitis (eczema) or lichen simplex chronicus AND the following: 1. Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Topical antihistamine (see Appendix I) b. High potency topical corticosteroid (see Appendix II) 2. Physician agrees to taper patient’s dose to the FDA recommended dose, and after tapered will only use for short-term pruritus relief (up to 8 days) a. Patients using over 60 grams of topical doxepin in 90 days be required to taper to 60 grams topical doxepin within 90 days Prior - Approval Limits Quantity 180 grams for 90 days Duration 3 months ___________________________________________________________________ Prior – Approval Renewal Requirements None (see appendix below) Doxepin 5% cream FEP Clinical Rationale DOXEPIN CREAM 5% (Prudoxin, Zonalon) APPENDIX I Drug Dosage Form Diphenhydramine Cream Phenyltoloxamine Lotion/ Cream Tripelennamine Cream Phendiamine Cream APPENDIX II Relative Potency of Selected Topical Corticosteroid Drug ProductsDosage Form Strength I. Very high potency Augmented betamethasone Ointment, Gel 0.05% dipropionate Clobetasol propionate Cream, Ointment 0.05% Diflorasone diacetate Ointment 0.05% Halobetasol propionate Cream, Ointment 0.05% II. High potency Amcinonide Cream, Lotion, 0.1% Augmented betamethasone Cream,Ointment Lotion 0.05% dipropionate Betamethasone Cream, Ointment 0.05% Betamethasonedipropionate valerate Ointment 0.1% Desoximetasone Cream, Ointment 0.25% Gel 0.05% Diflorasone diacetate Cream, Ointment 0.05% (emollient base) Fluocinonide Cream, Ointment, Gel 0.05% Halcinonide Cream, Ointment 0.1% Triamcinolone acetonide Cream, Ointment 0.5% III.
    [Show full text]